Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2025 Earnings Presentation
17 slides from Vita Life Sciences's earnings presentation, Aug 25, 2025
Slide 1: Half Year Presentation
Half Year Presentation June 2025
Slide 2: Managing Director message
Managing Director Andrew O’Keefe We are pleased to report a strong performance for the first six months ended June 2025. Our organisation’s fundamentals remain solid, reflecting the strength of our strategy and product offerings. The Board and management are committed to sustaining growth whilst mak
Slide 3: About Vita Life Sciences
About Vita Life Sciences Who we are Our purpose Our mission Our Vision Our values C.A.R.E Developers and distributors To provide people with Intelligently crafted To provide health solutions Considered approach of premium and trusted formulations that formulations, combing that cater to people in As
Slide 4: Financial Highlights
REVENUE Financial Highlights PBT $45.5M $6.8M UP 15% VS PCP INTERIM • Record first half Revenue UP 13% VS PCP DIVIDEND 4.5CPS • Gross profit margin ↑ 2% to 60% EQUITY CASH • Cash conversion: strong 109% $52.6M RESERVES • Strong balance sheet with no borrowings $29.4M (no borrowing) • Share buyback:
Slide 5: Half Year Results
Half Year Results 2025 2024 REVENUE Half year ended June $’m $’m Revenue 45.5 39.5 $45.5M EBITDA 7.0 5.9 EBIT 6.5 5.6 Profit before tax 6.8 6.0 PBT Profit after tax 4.8 4.3 EPS (Basic – cents/ share) 8.61 7.84 $6.8M Dividend (cents / share) 4.5 3. 5
Slide 6: Balance Sheet
Balance Sheet Jun 2025 Dec 2024 Balance Sheet as at $’m $’m Current assets 59.2 58.9 Non-current assets 15.4 13.0 Total assets 74.6 71.9 Current liabilities 20.1 19.3 Non-current liabilities 1.9 0.3 Total Liabilities 22.0 19.6 Net Assets 52.6 52.3
Slide 7: Cash Flow
Cash Flow 2025 2024 GROSS Cash Flow for the half year ended June OPERATING $’m $’m CASH FLOW Receipts from customers Payments to suppliers and employees 47.0 (39.5) 40.4 (36.6) 109% Gross operating cash flow 7.5 3.8 EBITDA 6.9 5.9 Gross operating cash flow / EBITDA 109% 65% Net interest 0.2 0.5 CASH
Slide 8: Operational Highlights
Operational Highlights Segment performance - Broad based growth across core markets, supported by strong performances across all major channels and positive consumer sentiment. • Australia up 8% • Malaysia & Singapore up 54% Market initiatives • Continued distribution expansion in Australia, Malaysi
Slide 9: Our people, our markets, our partners
Our people Our markets Our partners We have over 300 employees in the Vita Life Sciences Group We continue to evolve and expand our global presence. Our products are available across some of the biggest offline across Australia, Malaysia, Singapore, China, Indonesia and We are currently in 6 markets
Slide 10: Marketing
Marketing Our marketing investment combines global scale with a deep understanding of local audiences. We connect with millions of consumers through coordinated activity across television, digital, social, radio, outdoor, print, and in-store channels. By integrating these platforms, we ensure our ca
Slide 11: Y vitatesit
Y vitatesit Sereemom jh 454455 E a NX VITA LIFE
Slide 12: 2025 NPD H1
2025 NPD H1 There are currently over 350 products 11 new products registered across the business. launched across Australia, Malaysia and Singapore.
Slide 13: Social impact & corporate responsibility
Social impact & corporate responsibility At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We have developed partnershi
Slide 14: Strategic priorities
Strategic priorities Our pillars ail BRAND BUILDING Key initiatives to support our pillars Focus on community lead Launch national Increased marketing ha marketing campaigns across training portal for the investment across Vietnam, ple NEO peeing Malaysia and Singapore Australian market China, and I
Slide 15: Outlook
Outlook The Board is encouraged by the Group’s first half performance, particularly the strength in Australia, Malaysia and Singapore and expects the momentum to be maintained going into the second half. The Group remains committed to delivering full year revenue and profit before tax growth over PC
Slide 16: Contact details
© +612 9545 2633 Suite 802, Level 8, 1-5 Chalmers Crescent Mascot NSW 2020 Australia enquiries@vitalifesciences.com.au ANDREW O'KEEFE CHIN LKHOO @ vitalifesciences.com MANAGING DIRECTOR CHIEF FINANCIAL OFFICER NA VITA LIFE
Slide 17: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences or VLS) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitati